Intercept Pharmaceuticals Inc (NASDAQ:ICPT) Director Luca Benatti acquired 1,200 shares of the firm’s stock in a transaction on Tuesday, May 14th. The shares were acquired at an average price of $83.50 per share, with a total value of $100,200.00. Following the completion of the transaction, the director now directly owns 7,556 shares in the company, valued at approximately $630,926. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.
ICPT opened at $86.83 on Friday. Intercept Pharmaceuticals Inc has a fifty-two week low of $65.63 and a fifty-two week high of $133.74. The company has a debt-to-equity ratio of 19.41, a current ratio of 3.72 and a quick ratio of 3.72. The stock has a market cap of $2.63 billion, a PE ratio of -8.00 and a beta of 1.49.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($3.03) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.57) by ($0.46). Intercept Pharmaceuticals had a negative return on equity of 617.23% and a negative net margin of 162.49%. The firm had revenue of $52.25 million for the quarter, compared to analysts’ expectations of $52.15 million. During the same period last year, the business earned ($3.22) earnings per share. The firm’s revenue for the quarter was up 45.3% on a year-over-year basis. On average, research analysts forecast that Intercept Pharmaceuticals Inc will post -9.78 EPS for the current fiscal year.
A number of equities research analysts have commented on the company. BidaskClub upgraded Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday. Wedbush restated an “outperform” rating and set a $243.00 price objective (down from $251.00) on shares of Intercept Pharmaceuticals in a research report on Monday. B. Riley set a $169.00 price objective on Intercept Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, April 12th. Wells Fargo & Co raised their price objective on Intercept Pharmaceuticals from $99.00 to $104.00 and gave the stock a “market perform” rating in a research report on Friday, April 12th. Finally, Zacks Investment Research upgraded Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 15th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and seventeen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $145.67.
WARNING: “Intercept Pharmaceuticals Inc (ICPT) Director Luca Benatti Acquires 1,200 Shares” was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.baseballdailydigest.com/news/2019/05/17/intercept-pharmaceuticals-inc-icpt-director-luca-benatti-acquires-1200-shares.html.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
Featured Story: Certificate of Deposit (CD)
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.